A molecular subtype of glioblastoma that is associated with younger age at presentation and is characterized by p53 mutations and PDGFRa amplifications.
Comprehensive, easy-to-understand information about this condition
How we create this content →Documentation on proneural glioblastoma is limited due to its rarity and the complexity of glioblastoma as a whole. The condition affects a relatively small number of individuals, which restricts the scope of systematic clinical studies. Additionally, the genetic basis and clinical features are still being characterized, leading to gaps in the available literature.
To navigate your care effectively, consider seeking a neuro-oncologist with expertise in glioblastoma and its subtypes. They can provide specialized insights into treatment options and clinical trials. Additionally, resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org can offer support and information. While no patient organizations are currently identified for proneural glioblastoma, staying connected with research initiatives may provide opportunities for participation in natural history studies.
There are several orphan drugs designated for proneural glioblastoma, including (1-hydroxy-2-oxopiperidin-3-yl)phosphonic acid and nivolumab, among others. However, no clinical trial data is currently available. For more information on ongoing research, you can search for related studies on ClinicalTrials.gov.
Actionable guidance for navigating care for proneural glioblastoma
To navigate your care effectively, consider seeking a neuro-oncologist with expertise in glioblastoma and its subtypes. They can provide specialized insights into treatment options and clinical trials. Additionally, resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org can offer support and information. While no patient organizations are currently identified for proneural glioblastoma, staying connected with research initiatives may provide opportunities for participation in natural history studies.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Documentation on proneural glioblastoma is limited due to its rarity and the complexity of glioblastoma as a whole. The condition affects a relatively small number of individuals, which restricts the scope of systematic clinical studies. Additionally, the genetic basis and clinical features are still being characterized, leading to gaps in the available literature.
To navigate your care effectively, consider seeking a neuro-oncologist with expertise in glioblastoma and its subtypes. They can provide specialized insights into treatment options and clinical trials. Additionally, resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org can offer support and information. While no patient organizations are currently identified for proneural glioblastoma, staying connected with research initiatives may provide opportunities for participation in natural history studies.
There are several orphan drugs designated for proneural glioblastoma, including (1-hydroxy-2-oxopiperidin-3-yl)phosphonic acid and nivolumab, among others. However, no clinical trial data is currently available. For more information on ongoing research, you can search for related studies on ClinicalTrials.gov.
Actionable guidance for navigating care for proneural glioblastoma
To navigate your care effectively, consider seeking a neuro-oncologist with expertise in glioblastoma and its subtypes. They can provide specialized insights into treatment options and clinical trials. Additionally, resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org can offer support and information. While no patient organizations are currently identified for proneural glioblastoma, staying connected with research initiatives may provide opportunities for participation in natural history studies.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Documentation on proneural glioblastoma is limited due to its rarity and the complexity of glioblastoma as a whole. The condition affects a relatively small number of individuals, which restricts the scope of systematic clinical studies. Additionally, the genetic basis and clinical features are still being characterized, leading to gaps in the available literature.
To navigate your care effectively, consider seeking a neuro-oncologist with expertise in glioblastoma and its subtypes. They can provide specialized insights into treatment options and clinical trials. Additionally, resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org can offer support and information. While no patient organizations are currently identified for proneural glioblastoma, staying connected with research initiatives may provide opportunities for participation in natural history studies.
There are several orphan drugs designated for proneural glioblastoma, including (1-hydroxy-2-oxopiperidin-3-yl)phosphonic acid and nivolumab, among others. However, no clinical trial data is currently available. For more information on ongoing research, you can search for related studies on ClinicalTrials.gov.
Actionable guidance for navigating care for proneural glioblastoma
To navigate your care effectively, consider seeking a neuro-oncologist with expertise in glioblastoma and its subtypes. They can provide specialized insights into treatment options and clinical trials. Additionally, resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org can offer support and information. While no patient organizations are currently identified for proneural glioblastoma, staying connected with research initiatives may provide opportunities for participation in natural history studies.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Consider asking your healthcare providers these condition-specific questions
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.